PROSTATE-SPECIFIC ANTIGEN AND OTHER PROGNOSTIC FACTORS IN PATIENTS WITH HORMONE-RESISTANT PROSTATIC-CANCER UNDERGOING EXPERIMENTAL TREATMENT

被引：22

作者：

FOSSA, SD

PAUS, E

LINDEGAARD, M

NEWLING, DWW

机构：

[1] NORWEGIAN RADIUM HOSP,DEPT CLIN BIOCHEM,N-0310 OSLO 3,NORWAY

[2] NORWEGIAN RADIUM HOSP,DEPT NUCL MED,N-0310 OSLO 3,NORWAY

[3] FREE UNIV AMSTERDAM,ACAD HOSP,DEPT UROL,1007 MC AMSTERDAM,NETHERLANDS

[4] NORWEGIAN RADIUM HOSP,CENT LAB,N-0310 OSLO 3,NORWAY

来源：

BRITISH JOURNAL OF UROLOGY | 1992年 / 69卷 / 02期

关键词：

D O I：

10.1111/j.1464-410X.1992.tb15491.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

In 58 patients with progressive hormone-resistant metastatic cancer of the prostate, prostate-specific antigen (PSA) > 100-mu-g/l, haemoglobin < 12.0 g/dl and pronounced fatigue were found to be independent adverse prognostic factors. These risk factors distinguished a subgroup of patients with a median survival of 9 months (none or only 1 risk factor present) from a subgroup with a median survival of 4 months (greater-than-or-equal-to 2 risk factors present). The clinician should be reluctant to enter patients from the second group into complicated and resource-demanding clinical studies, particularly if such trials require frequent and inconvenient follow-up examinations.

引用

页码：175 / 179

页数：5

共 14 条

[1]

Ahmann F.R., Schifman R.B., Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer, J. Urol., 137, pp. 431-434, (1987)

[2]

Berry W.R., Laszlo J., Cox E., Et al., Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate, Cancer, 44, pp. 763-775, (1979)

[3]

Beynon L.L., Chisholm G.D., The stable state is not an objective response in hormone‐escaped carcinoma of prostate, Br. J. Urol., 56, pp. 702-705, (1984)

[4]

Cooper E.H., Armitage T.G., The biochemical monitoring of prostate cancer, EORTC Genitourinary Group Monograph 7: Prostate Cancer and Testicular Cancer, pp. 23-27, (1990)

[5]

de Voogt H.J., Suciu S., Sylvester R., Et al., Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials, J. Urol., 141, pp. 883-888, (1989)

[6]

Fossa S.D., Aaronson N., da Calais, Et al., Quality of life in patients with muscle‐infiltrating bladder cancer and hormone‐resistant prostatic cancer, Eur. Urol., 16, pp. 335-339, (1989)

[7]

Fossa S.D., Aaronson N., Treatment aims in hormone‐resistant prostatic cancer, Eur. J. Cancer Clin. Oncol, (1990)

[8]

Fossa S.D., Aaronson N.K., Newling D., Et al., Subjective response to treatment of hormone resistant metastatic prostatic cancer: Results of a Quality of Life study in patients receiving either Mitomycin C or Estracyt–EORTC GU Group Protocol No. 30865, Eur. J. Cancer Clin. Oncol., 26, pp. 1133-1136, (1991)

[9]

Ishikawa S., Soloway M.S., van der Zwaag R., Et al., Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer, J. Urol., 141, pp. 1139-1142, (1989)

[10]

Kuriyama M., Wang M.C., Lee C., Et al., Use of human prostate‐specific antigen in monitoring prostate cancer, Cancer Res., 41, pp. 3874-3876, (1981)

← 1 2 →